These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption. Cheng Z; Zhang J; Liu H; Li Y; Zhao Y; Yang E Drug Metab Dispos; 2010 Aug; 38(8):1355-61. PubMed ID: 20427691 [TBL] [Abstract][Full Text] [Related]
5. Blood-brain barrier P-glycoprotein function in Alzheimer's disease. van Assema DM; Lubberink M; Bauer M; van der Flier WM; Schuit RC; Windhorst AD; Comans EF; Hoetjes NJ; Tolboom N; Langer O; Müller M; Scheltens P; Lammertsma AA; van Berckel BN Brain; 2012 Jan; 135(Pt 1):181-9. PubMed ID: 22120145 [TBL] [Abstract][Full Text] [Related]
6. Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation. Boado RJ; Zhang Y; Zhang Y; Xia CF; Pardridge WM Bioconjug Chem; 2007; 18(2):447-55. PubMed ID: 17315944 [TBL] [Abstract][Full Text] [Related]
11. [Role of the blood-brain barrier in Alzheimer's disease]. Gosselet F; Candela P; Cecchelli R; Fenart L Med Sci (Paris); 2011 Nov; 27(11):987-92. PubMed ID: 22130026 [TBL] [Abstract][Full Text] [Related]
12. Nanomedicine for the treatment of Alzheimer's disease. Gregori M; Masserini M; Mancini S Nanomedicine (Lond); 2015; 10(7):1203-18. PubMed ID: 25929574 [TBL] [Abstract][Full Text] [Related]
13. Age-associated dysregulation of microglial activation is coupled with enhanced blood-brain barrier permeability and pathology in APP/PS1 mice. Minogue AM; Jones RS; Kelly RJ; McDonald CL; Connor TJ; Lynch MA Neurobiol Aging; 2014 Jun; 35(6):1442-52. PubMed ID: 24439957 [TBL] [Abstract][Full Text] [Related]
14. Modulators of IgG penetration through the blood-brain barrier: Implications for Alzheimer's disease immunotherapy. Finke JM; Banks WA Hum Antibodies; 2017; 25(3-4):131-146. PubMed ID: 28035915 [TBL] [Abstract][Full Text] [Related]
16. Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer's Disease. Yamazaki Y; Kanekiyo T Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28902142 [TBL] [Abstract][Full Text] [Related]
17. High fat diet exacerbates Alzheimer's disease-related pathology in APPswe/PS1 mice. Thériault P; ElAli A; Rivest S Oncotarget; 2016 Oct; 7(42):67808-67827. PubMed ID: 27661129 [TBL] [Abstract][Full Text] [Related]
18. Is P-glycoprotein involved in amyloid-β elimination across the blood-brain barrier in Alzheimer's disease? Ohtsuki S; Ito S; Terasaki T Clin Pharmacol Ther; 2010 Oct; 88(4):443-5. PubMed ID: 20856239 [No Abstract] [Full Text] [Related]
19. The blood brain barrier in Alzheimer's disease. Chakraborty A; de Wit NM; van der Flier WM; de Vries HE Vascul Pharmacol; 2017 Feb; 89():12-18. PubMed ID: 27894893 [TBL] [Abstract][Full Text] [Related]
20. Managing vascular disease could reduce Alzheimer's risk. Prevention and proper treatment can help prevent impaired blood flow to the brain. Duke Med Health News; 2013 Jan; 19(1):7. PubMed ID: 23762974 [No Abstract] [Full Text] [Related] [Next] [New Search]